Wecome Pharmaceutical Co Ltd
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern traditional Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly k… Read more
Wecome Pharmaceutical Co Ltd (300878) - Net Assets
Latest net assets as of September 2025: CN¥1.03 Billion CNY
Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) has net assets worth CN¥1.03 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.49 Billion) and total liabilities (CN¥458.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.03 Billion |
| % of Total Assets | 69.2% |
| Annual Growth Rate | 37.85% |
| 5-Year Change | -15.21% |
| 10-Year Change | 802.63% |
| Growth Volatility | 54.3 |
Wecome Pharmaceutical Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Wecome Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Wecome Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual net assets of Wecome Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.17 Billion | -16.60% |
| 2023-12-31 | CN¥1.41 Billion | -0.29% |
| 2022-12-31 | CN¥1.41 Billion | +0.18% |
| 2021-12-31 | CN¥1.41 Billion | +1.78% |
| 2020-12-31 | CN¥1.38 Billion | +166.31% |
| 2019-12-31 | CN¥519.84 Million | +32.00% |
| 2018-12-31 | CN¥393.83 Million | +28.68% |
| 2017-12-31 | CN¥306.05 Million | +45.12% |
| 2016-12-31 | CN¥210.90 Million | +62.17% |
| 2015-12-31 | CN¥130.04 Million | +66.25% |
| 2014-12-31 | CN¥78.22 Million | +127.72% |
| 2013-12-31 | CN¥34.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Wecome Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2973.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥316.91 Million | 27.38% |
| Common Stock | CN¥144.79 Million | 12.51% |
| Other Comprehensive Income | CN¥65.19 Million | 5.63% |
| Other Components | CN¥630.77 Million | 54.49% |
| Total Equity | CN¥1.16 Billion | 100.00% |
Wecome Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Wecome Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DOUGLAS ELLIMAN DL-01
F:8OT
|
$143.47 Million |
|
Ginebra San Miguel Inc
PINK:GBSMF
|
$143.53 Million |
|
Jiangsu Teeyer Intelligent Equipment Co.,Ltd.
SHG:603273
|
$143.54 Million |
|
CAMP4 THERAPEUTICS CORPORATION
NASDAQ:CAMP
|
$143.59 Million |
|
GENERALFINANCE SPA
F:VG30
|
$143.32 Million |
|
iHeartMedia Inc
PINK:IHRTB
|
$143.32 Million |
|
AGIOE ORD A (SHH) EQSW Exp:
SHG:688450
|
$143.31 Million |
|
Power Metallic Mines Inc.
F:IVV1
|
$143.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wecome Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,390,601,189 to 1,157,666,559, a change of -232,934,630 (-16.8%).
- Net loss of 147,426,253 reduced equity.
- Dividend payments of 44,399,822 reduced retained earnings.
- Share repurchases of 49,998,351 reduced equity.
- Other comprehensive income increased equity by 65,194,788.
- Other factors decreased equity by 56,304,992.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-147.43 Million | -12.73% |
| Dividends Paid | CN¥44.40 Million | -3.84% |
| Share Repurchases | CN¥50.00 Million | -4.32% |
| Other Comprehensive Income | CN¥65.19 Million | +5.63% |
| Other Changes | CN¥-56.30 Million | -4.86% |
| Total Change | CN¥- | -16.75% |
Book Value vs Market Value Analysis
This analysis compares Wecome Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 30.50x to 3.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.94 | CN¥28.53 | x |
| 2014-12-31 | CN¥1.99 | CN¥28.53 | x |
| 2015-12-31 | CN¥1.20 | CN¥28.53 | x |
| 2016-12-31 | CN¥1.94 | CN¥28.53 | x |
| 2017-12-31 | CN¥2.82 | CN¥28.53 | x |
| 2018-12-31 | CN¥3.61 | CN¥28.53 | x |
| 2019-12-31 | CN¥3.59 | CN¥28.53 | x |
| 2020-12-31 | CN¥9.54 | CN¥28.53 | x |
| 2021-12-31 | CN¥9.65 | CN¥28.53 | x |
| 2022-12-31 | CN¥9.66 | CN¥28.53 | x |
| 2023-12-31 | CN¥10.38 | CN¥28.53 | x |
| 2024-12-31 | CN¥8.09 | CN¥28.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wecome Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.98%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.43x
- Recent ROE (-12.73%) is below the historical average (20.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 58.65% | 14.62% | 1.26x | 3.18x | CN¥16.38 Million |
| 2014 | 26.49% | 13.52% | 0.89x | 2.21x | CN¥12.90 Million |
| 2015 | 38.47% | 24.08% | 0.94x | 1.71x | CN¥37.02 Million |
| 2016 | 38.34% | 28.66% | 0.90x | 1.49x | CN¥59.76 Million |
| 2017 | 31.09% | 23.41% | 0.85x | 1.57x | CN¥64.55 Million |
| 2018 | 22.29% | 15.20% | 0.90x | 1.63x | CN¥48.39 Million |
| 2019 | 24.24% | 19.63% | 0.73x | 1.68x | CN¥74.03 Million |
| 2020 | 9.83% | 21.81% | 0.38x | 1.18x | CN¥-2.31 Million |
| 2021 | 6.91% | 15.25% | 0.37x | 1.21x | CN¥-43.24 Million |
| 2022 | 3.49% | 9.19% | 0.28x | 1.37x | CN¥-91.02 Million |
| 2023 | -0.58% | -1.55% | 0.25x | 1.47x | CN¥-147.10 Million |
| 2024 | -12.73% | -41.98% | 0.21x | 1.43x | CN¥-263.19 Million |
Industry Comparison
This section compares Wecome Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wecome Pharmaceutical Co Ltd (300878) | CN¥1.03 Billion | 58.65% | 0.45x | $143.32 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |